EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

COMBAT ‐ MS : A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab

Fredrik Piehl, Peter Alping iD, Suvi Virtanen, Simon Englund iD, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould iD, Jan Lycke, Johan Mellergård und 5 weitere

Annals of Neurology · 2024

DOI: 10.1002/ana.27012 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Neurology, 2024. Verfasst von Fredrik Piehl und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Rituximab, Immunologic Factors, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Patient-Centered Outcomes Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess comparative effectiveness, safety, and tolerability of off‐label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS).

Methods

A Swedish cohort study of persons with relapsing–remitting MS, age 18 to 75 years at inclusion and with a first therapy start or a first therapy switch between 2011 and 2018. Low‐dose rituximab was compared with MS‐approved therapies. Primary outcomes were proportions with 12 months confirmed disability worsening and change in MS Impact Scale‐29 (MSIS‐29) scores, respectively. Secondary endpoints included relapses, therapy discontinuation, and serious adverse events. Analyses used an intention‐to‐treat approach and were adjusted for demographics, MS features, and health characteristics.

Results

We included 2,449 participants as first therapy start and 2,463 as first therapy switch. Proportions with disability worsening at 3 years were 9.1% for rituximab as first therapy and 5.1% after therapy switch, with no differences to MS‐approved comparators. Worsening on rituximab was mostly independent of relapses. MSIS‐29 with rituximab at 3 years improved by 1.3/8.4 points (physical/psychological) for first disease‐modifying therapy (DMT) and 0.4/3.6 for DMT switch, and was mostly similar across therapies. Rituximab had lower relapse rates and higher therapy persistence in both groups. The rate of hospital‐treated infections was higher with rituximab after a therapy switch, but not as a first therapy.

Interpretation

This population‐based real‐world cohort study found low rates of disability progression, mostly independent of relapses, and without significant differences between rituximab and MS‐approved comparators. Rituximab led to lower rates of inflammatory activity and higher treatment persistence, but was associated with an increased rate of serious infections. ANN NEUROL 2024;96:678–693

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabImmunologic FactorsMultiple Sclerosis, Relapsing-RemittingHumansAdultMiddle AgedFemaleMaleCohort StudiesSwedenAgedYoung AdultAdolescentNatalizumabTreatment OutcomeMultiple Sclerosis

Substanzen

RituximabImmunologic FactorsNatalizumab

Autor:innen und Institutionen

  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Neurology, Uppsala University Hospital, and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Department of Neurology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

ORCID-Profile: Peter Alping, Simon Englund, Annette Langer-Gould, Thomas Frisell

Förderung

  • Patient-Centered Outcomes Research Institute

Zitieren

APA

Piehl, F., Alping, P., Virtanen, S., Englund, S., Burman, J., Fink, K., Fogdell-Hahn, A., Gunnarsson, M., Hillert, J., Langer-Gould, A., Lycke, J., Mellergård, J., Nilsson, P., Olsson, T., Salzer, J., Svenningsson, A., & Frisell, T. (2024). COMBAT ‐ MS : A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Annals of Neurology. https://doi.org/10.1002/ana.27012

Vancouver

Piehl F, Alping P, Virtanen S, Englund S, Burman J, Fink K, et al. COMBAT ‐ MS : A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Annals of Neurology. 2024. doi:10.1002/ana.27012

BibTeX
@article{Piehl2024,
  author = {Piehl, Fredrik and Alping, Peter and Virtanen, Suvi and Englund, Simon and Burman, Joachim and Fink, Katharina and Fogdell-Hahn, Anna and Gunnarsson, Martin and Hillert, Jan and Langer-Gould, Annette and Lycke, Jan and Mellergård, Johan and Nilsson, Petra and Olsson, Tomas and Salzer, Jonatan and Svenningsson, Anders and Frisell, Thomas},
  title = {COMBAT ‐ MS : A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab},
  journal = {Annals of Neurology},
  year = {2024},
  doi = {10.1002/ana.27012}
}
Kostenlos starten →